These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31964625)

  • 41. Production and characterization of tumor infiltrating lymphocyte clones derived from B16-F10 murine melanoma.
    Maeda K; Lafreniere R; Jerry LM
    J Invest Dermatol; 1991 Aug; 97(2):183-9. PubMed ID: 2071934
    [TBL] [Abstract][Full Text] [Related]  

  • 42. T-cell receptor gene therapy of established tumors in a murine melanoma model.
    Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
    J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rescue of tumor-infiltrating lymphocytes from activation-induced cell death enhances the antitumor CTL response in CD5-deficient mice.
    Tabbekh M; Franciszkiewicz K; Haouas H; Lécluse Y; Benihoud K; Raman C; Mami-Chouaib F
    J Immunol; 2011 Jul; 187(1):102-9. PubMed ID: 21622855
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
    Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
    Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
    Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of functional heterogeneity in the CD8 subset with T cells from T cell receptor-transgenic mice.
    Gaugler B; Schmitt-Verhulst AM; Guimezanes A
    Eur J Immunol; 1993 Aug; 23(8):1851-8. PubMed ID: 8344346
    [TBL] [Abstract][Full Text] [Related]  

  • 48. P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors.
    Romagnani A; Rottoli E; Mazza EMC; Rezzonico-Jost T; De Ponte Conti B; Proietti M; Perotti M; Civanelli E; Perruzza L; Catapano AL; Baragetti A; Tenedini E; Tagliafico E; Falzoni S; Di Virgilio F; Norata GD; Bicciato S; Grassi F
    Cancer Res; 2020 Sep; 80(18):3906-3919. PubMed ID: 32699136
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Th9 Cells Represent a Unique Subset of CD4
    Lu Y; Wang Q; Xue G; Bi E; Ma X; Wang A; Qian J; Dong C; Yi Q
    Cancer Cell; 2018 Jun; 33(6):1048-1060.e7. PubMed ID: 29894691
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2000 Jan; 164(2):916-25. PubMed ID: 10623840
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells.
    Santin AD; Bellone S; Ravaggi A; Pecorelli S; Cannon MJ; Parham GP
    Obstet Gynecol; 2000 Sep; 96(3):422-30. PubMed ID: 10960637
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
    Yin W; Song Y; Liu Q; Wu Y; He R
    Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
    J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
    Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
    J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice.
    Wang L; Fan J; Thompson LF; Zhang Y; Shin T; Curiel TJ; Zhang B
    J Clin Invest; 2011 Jun; 121(6):2371-82. PubMed ID: 21537079
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation.
    Li SY; Liu Y; Xu CF; Shen S; Sun R; Du XJ; Xia JX; Zhu YH; Wang J
    J Control Release; 2016 Jun; 231():17-28. PubMed ID: 26829099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.
    Hu J; Sun C; Bernatchez C; Xia X; Hwu P; Dotti G; Li S
    Clin Cancer Res; 2018 Jun; 24(12):2920-2934. PubMed ID: 29391351
    [No Abstract]   [Full Text] [Related]  

  • 58. Tumor infiltrating lymphocytes in ovarian cancer.
    Santoiemma PP; Powell DJ
    Cancer Biol Ther; 2015; 16(6):807-20. PubMed ID: 25894333
    [TBL] [Abstract][Full Text] [Related]  

  • 59. mTOR inhibition potentiates cytotoxicity of Vγ4 γδ T cells via up-regulating NKG2D and TNF-α.
    Cao G; Wang Q; Li G; Meng Z; Liu H; Tong J; Huang W; Liu Z; Jia Y; Wei J; Chi H; Yang H; Zhao L; Wu Z; Hao J; Yin Z
    J Leukoc Biol; 2016 Nov; 100(5):1181-1189. PubMed ID: 27256566
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
    Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
    Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.